Hoth Therapeutics reports results from multi-dose study of HT-KIT

Hoth Therapeutics (HOTH) announced encouraging preclinical results from a multi-dose study of HT-KIT, its investigational oncology candidate targeting the c-KIT pathway. The study demonstrated a clear dose-responsive effect on liver mass with no observable toxicity or organ pathology, reinforcing the favorable safety profile of HT-KIT as the Company prepares for further toxicology studies and regulatory advancement. Key Preclinical Findings (HT-KIT): Liver weight increased from 1.11g at 0 mg/kg to 1.32g at 3.0 mg/kg, consistent with pharmacological engagement; Kidney and spleen weights remained stable, indicating no off-target or systemic toxicity; Thymus and other critical organ weights were within normal range across all groups; No gross pathology or visible lesions observed in any treated animal. Hoth Therapeutics expects to initiate GLP toxicology studies, with plans to submit an Investigational New Drug application soon after.